Free shipping on all orders over $ 500

Cilastatin

Cat. No. M6090
Cilastatin Structure
Size Price Availability Quantity
10mg USD 90 In stock
50mg USD 380 In stock
Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >99%
  • COA
  • MSDS
Biological Activity

Cilastatin attenuates VAN-induced acute renal failure in vitro by decreasing apoptosis without affecting antibacterial activity. This effect could be related, at least in part, to the reduction in accumulation of the drug in cells. Therefore, cilastatin could represent a novel therapeutic approach in reducing VAN-induced renal damage without compromising bactericidal efficacy.

Protocol
Cell Experiment
Cell lines Proximal Tubular Primary Cell
Preparation method Cells were pretreated with VAN (0.6, 3, and 6 mg/mL) alone or in combination with cilastatin (200 μg/mL) before being trypsinized, washed twice with PBS, and incubated for 30 min in the dark in 100 μL buffer containing 5 μL fluorescein isothiocyanate- (FITC-) labeled annexin V and 5 μL PI for flow cytometry.
Concentrations 200 μg/mL
Incubation time 24 h
Animal Experiment
Animal models
Formulation
Dosages
Administration
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 358.45
Formula C16H26N2O5S
CAS Number 82009-34-5
Purity >99%
Solubility 10 mM in DMSO
Storage at -20°C
References

Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity.
Humanes B, et al. Biomed Res Int. 2015;2015:704382. PMID: 26504822.

Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
Ramirez J, et al. Antimicrob Agents Chemother. 2013 Apr;57(4):1756-62. PMID: 23357775.

Related Products
Wilforine

Wilforine is a sesquiterpene pyridine alkaloid; important bioactive compound in T. wilfordii plants, and is effective in treating idiopathic pulmonary fibrosis.

Wilfortrine

Wilfortrine is an immunomodulatory compound isolated from Tripterygium wilfordii.

Etanercept

Etanercept is a dimeric fusion protein consisting of two ligand-binding domains of human p75 tumor necrosis factor receptor and the human IgG1 Fc portion.

Tocilizumab

Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor, MW: 148 KD.

Lambrolizumab

Lambrolizumabis a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Cilastatin supplier, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.